Telesis Bio Stock Is Soaring Wednesday: What's Going On?
Telesis Bio Stock Is Soaring Wednesday: What's Going On?
"This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA's high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries," said Telesis Bio Inc (NASDAQ:TBIO) shares are soaring in extended trading Wednesday after the company announced a partnership to revolutionize DNA and mRNA synthesis.
Telesis生物公司（NASDAQ:TBIO）股票在周三盘后交易中飙升，因该公司宣布与合作伙伴合作，革新DNA和mRNA合成。
What Happened: Telesis Bio reached a new partnership with laboratory automation and innovation company Beckman Coulter Life Sciences to create efficient and scalable biofoundries and deliver solutions for DNA synthesis.
发生了什么： Telesis生物与实验室自动化和创新公司贝克曼库尔特生命科学达成了新合作，以创建高效可扩展的生物工厂，并为DNA合成提供解决方案。
The partnership will integrate Telesis Bio's Gibson SOLA Enzymatic Synthesis technology with Beckman Coulter's new Biomek Echo One System, further expanding its flexibility to synthesize biology.
该合作将Telesis生物的Gibson SOLA酶合成技术与Beckman Coulter的新Biomek Echo One系统相结合，进一步扩展其生物合成灵活性。
"This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA's high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries," said Eric Esser, CEO of Telesis Bio.
“这一合作标志着合成生物学的重要里程碑。通过将Gibson SOLA的高保真、可扩展和无毒的DNA合成能力与贝克曼库尔特生命科学的自动化专业知识相结合，我们正在为现场生物工厂树立新的标准，” Telesis Bio首席执行官埃里克·埃瑟说。
"This collaboration empowers researchers to greatly improve productivity through faster, more reliable and innovative solutions, driving forward the next generation of therapeutic and diagnostic advancements."
“这一合作使研究人员能够通过更快速、更可靠和更创新的解决方案大大提高生产率，推动下一代治疗和诊断进步的发展。”
Telesis Bio provides non-toxic, high-fidelity and scalable DNA synthesis, empowering scientists to create novel, synthetic biology-enabled solutions.
Telesis生物提供无毒、高保真和可扩展的DNA合成，帮助科学家创造新颖的、合成生物学启用的解决方案。
Telesis Bio is considered a low-float stock with approximately 406,000 shares available for public trading, according to Benzinga Pro. It also had a market cap of less than $5 million as of Wednesday's close. Low-float, micro-cap stocks often trade with elevated volatility, which may help explain some of Telesis Bio's massive move after the bell.
根据Benzinga Pro的数据，Telesis生物被认为是一只低浮动股，大约有406,000股可供公开交易，截至周三收盘时的市值不到500万美元。低浮动、微型股通常具有较高的波动性，这可能有助于解释铃响后Telesis生物的大幅上涨中的一些原因。
TBIO Price Action: Telesis Bio shares were up 110.02% at $4.87 in after-hours trading Wednesday, according to Benzinga Pro.
TBIO价格走势：据Benzinga Pro报道，Telesis生物股票周三盘后交易中上涨110.02%，报4.87美元。
This illustration was generated using artificial intelligence via Midjourney.
此插图是通过Midjourney使用人工智能生成的。